Seizure Risk: Tobramycin vs Moxifloxacin
Moxifloxacin carries a documented seizure risk while tobramycin does not have established seizurogenic properties. Based on the available evidence, moxifloxacin poses the greater seizure risk between these two agents.
Evidence for Moxifloxacin's Seizure Risk
The FDA drug label for moxifloxacin explicitly warns that fluoroquinolones have been associated with an increased risk of central nervous system reactions, including convulsions 1. The label specifically states that moxifloxacin should be used cautiously in patients with known or suspected CNS disorders (such as epilepsy) or other risk factors that may predispose to seizures or lower the seizure threshold 1.
British Thoracic Society guidelines confirm that seizures are a serious adverse effect of moxifloxacin, recommending caution in patients with CNS disorders 2. The mechanism involves GABA antagonism and increased neuronal excitability 3.
Clinical Evidence
- A case report documented a 73-year-old patient who developed generalized tonic-clonic seizures on day 6 of moxifloxacin 400 mg IV daily 4
- Risk factors for moxifloxacin-induced seizures include: preexisting CNS disease, elderly age, female sex, lower body weight, and severe renal impairment 4
- A systematic review identified fluoroquinolones (particularly ciprofloxacin, but the class effect applies to moxifloxacin) as having low to very low evidence for seizure risk, with most cases occurring in patients with renal dysfunction, mental disorders, or prior seizures 5
Important Caveats for Moxifloxacin
The seizure risk is amplified when moxifloxacin is combined with NSAIDs, which may increase CNS effects 1. Concomitant use with theophylline also increases convulsion risk 2. The FDA label advises discontinuing moxifloxacin immediately if CNS reactions occur 1.
Evidence for Tobramycin
Tobramycin does not appear in any of the provided evidence as having seizurogenic properties. The extensive tuberculosis treatment guidelines from CDC/ATS discuss tobramycin's adverse effects in detail—focusing on ototoxicity, nephrotoxicity, and neuromuscular blockade—but seizures are not mentioned 6.
An experimental study testing 12 antibiotics for epileptogenic effects found that tobramycin had no epileptogenic effects in hippocampal slice preparations, whereas other aminoglycosides like gentamicin showed moderate epileptogenic properties 7.
The neurotoxicity profile of tobramycin (and streptomycin, a related aminoglycoside) consists primarily of:
- Circumoral paresthesias (common with streptomycin) 6
- Rare interaction with muscle relaxants causing respiratory muscle weakness 6
- No documented seizure activity
Clinical Decision Algorithm
When choosing between tobramycin and moxifloxacin:
If the patient has ANY of the following, avoid moxifloxacin:
- History of seizures or epilepsy
- CNS disorders (stroke, brain lesions, severe cerebral arteriosclerosis)
- Concurrent NSAID use
- Concurrent theophylline use
- Elderly with multiple risk factors
- Severe renal impairment
Tobramycin is the safer choice regarding seizure risk but requires monitoring for:
- Ototoxicity (audiometry at baseline and monthly)
- Nephrotoxicity (renal function monitoring)
- Dose adjustment in renal impairment 6
If moxifloxacin must be used despite seizure risk:
- Avoid NSAIDs and theophylline
- Monitor for early CNS symptoms (dizziness, confusion, tremors)
- Discontinue immediately if any CNS symptoms develop
- Consider baseline ECG (QT prolongation is another concern) 2
The choice between these agents should ultimately be driven by the specific infection being treated and susceptibility patterns, but from a pure seizure risk perspective, tobramycin is clearly the safer option 7.